Inhibition of Interleukin-17A, But Not Interleukin-17F, Signaling Lowers Blood Pressure, and Reduces End-Organ Inflammation in Angiotensin II–Induced Hypertension  by Saleh, Mohamed A. et al.
J A C C : B A S I C T O T R A N S L A T I O N A L S C I E N C E V O L . 1 , N O . 7 , 2 0 1 6
ª 2 0 1 6 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E AM E R I C A N
C O L L E G E O F C A R D I O L O G Y F O UN DA T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E R
T H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o mm o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .
I S S N 2 4 5 2 - 3 0 2 X
h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c b t s . 2 0 1 6 . 0 7 . 0 0 9PRECLINICAL RESEARCHInhibition of Interleukin-17A,
But Not Interleukin-17F, Signaling
Lowers Blood Pressure, and
Reduces End-Organ Inﬂammation in
Angiotensin II–Induced Hypertension
Mohamed A. Saleh, PHD,a,b Allison E. Norlander, BS,c Meena S. Madhur, MD, PHDa,cVISUAL ABSTRACTF
T
cD
A
H
D
In
MSaleh, M.A. et al. J Am Coll Cardiol Basic Trans Science. 2016;1(7):606–16.rom the aDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt Univ
ennessee; bDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura Un
epartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tenness
merican Heart Association Fellowship Award (14POST20420025) to Dr. Saleh, a training gra
ealth (NIH T32 HL069765-11A1) and an NIH NRSA Award (F31 HL127986) to Dr. Norlander, an
r. Madhur. Amgen provided some reagents used in this study. Dr. Madhur has received a re
c. All other authors have reported that they have no relationships relevant to the contents
anuscript received June 1, 2016; revised manuscript received July 7, 2016, accepted July 8,HIGHLIGHTS
 Hypertension is associated with an
increase in T-cell–derived cytokines such
IL-17A and IL-17F.
 Monoclonal antibodies to IL-17A, IL-17F,
IL-17RA, or isotype control antibodies
(IgG1) were administered twice weekly
during the last 2 weeks of a 4-week
angiotensin II infusion protocol in mice.
 Antibodies to IL-17A or IL-17RA, but not
IL-17F, lowered blood pressure by
30 mm Hg, attenuated renal and vascular
inﬂammation, and reduced renal trans-
forming growth factor beta levels
(a marker of renal ﬁbrosis) compared with
control IgG1 antibodies. All 3 experi-
mental antibodies blunted the progres-
sion of albuminuria.
 Monoclonal antibodies to IL-17A or
IL-17RA may be a useful adjunct treat-
ment for hypertension and the associated
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607SUMMARY
AB BAND ACRONYM S
Ang II = angiotensin II
ANOVA = analysis of variance
DOCA-salt =
deoxycorticosterone acetate
and high-salt diet
ELISA = enzyme-linked
immunosorbent assay
FDA = Food and Drug
Administration
Ig = immunoglobulinInﬂammatory cytokines play a major role in the pathophysiology of hypertension. The authors previously
showed that genetic deletion of interleukin (IL)-17A results in blunted hypertension and reduced renal/vascular
dysfunction. With the emergence of a new class of monoclonal antibody–based drugs for psoriasis and related
autoimmune disorders that target IL-17 signaling, the authors sought to determine whether these antibodies
could also reduce blood pressure, renal/vascular inﬂammation, and renal injury in a mouse model of hyper-
tension. The authors show that antibodies to IL-17A or the IL-17RA receptor subunit, but not IL-17F, may be a
novel adjunct treatment for hypertension and the associated end-organ dysfunction. (J Am Coll Cardiol Basic
Trans Science 2016;1:606–16) © 2016 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
nterleukin
RA = interleukin-17IL = i
IL-17receptor A
TGF = transforming growth
factorT here is now strong evidence that hyperten-sion is an inﬂammatory disease in whichT cells and T-cell–derived cytokines
contribute to blood pressure elevation and end-
organ damage (1,2). Our group was the ﬁrst to demon-
strate the critical role of the proinﬂammatory cytokine
interleukin (IL)-17A in hypertension and the accompa-
nying vascular dysfunction, using mice with genetic
deletion of IL-17A (3). Subsequently, Nguyen et al.
(4) showed that infusion of recombinant IL-17A into
mice raised blood pressure and impaired vascular
relaxation through phosphorylation of endothelial ni-
tric oxide synthase and reduced vascular nitric oxide
production. Recently, we showed that IL-17A contrib-
utes to angiotensin II (Ang II)-induced renal injury and
modulates the expression of renal sodium trans-
porters resulting in altered pressure natriuresis,
whereas the related cytokine, IL-17F, had little or no
effect on blood pressure, renal injury, and renal so-
dium chloride cotransporter activity (5,6).
The IL-17 cytokine family consists of 6 isoforms
(IL-17A through IL-17F) of which IL-17A and IL-17F
share the highest (50%) sequence homology (7). Both
IL-17A and IL-17F are produced by similar subsets of
immune cells and bind as homo- or heterodimers to the
same receptor complex composed of IL-17RA and IL-
17RC subunits (8). Although IL-17A has been widely
studied and found to play critical roles in the patho-
genesis of many autoimmune diseases such as psoria-
sis and multiple sclerosis (9), the role of IL-17F is less
well characterized. IL-17F has a lower afﬁnity for the
IL-17RA receptor subunit and has been found to have
overlapping, as well as distinctive functions, from IL-
17A (10).
IL-17A is the signature cytokine of a relatively
recently described subset of CD4þ T-helper cells
designated TH17 cells. However, a subset of CD8þ T
cells as well as gamma delta (gd) T cells (innate-like
unconventional T cells with a distinct T-cell receptor)can produce IL-17A under various conditions
(11). In fact, gd T cells are thought to be the
most prominent producers of IL-17A under
certain pathological conditions (12–14). Interestingly,
recent studies have demonstrated that salt can pro-
mote the production of pathogenic TH17 cells, thus
providing a potential link between high salt intake and
the development of hypertension (15,16).
In the current study, we sought to determine the
cellular source of IL-17 isoforms in the kidney and
vasculature of hypertensive animals, and determine
whether pharmacological inhibition of IL-17 signaling
can reduce blood pressure and ameliorate renal/
vascular inﬂammation and renal injury in a mouse
model of hypertension. A number of human mono-
clonal antibodies to IL-17A, IL-17F, or the IL-17RA re-
ceptor subunit are in development, clinical testing, or
Food and Drug Administration (FDA)-approved for the
treatment of psoriasis and related autoimmune disor-
ders (reviewed in Beringer et al. [9]). However, to date,
these drugs have not been tested in humans for their
efﬁcacy in hypertension or other cardiovascular dis-
orders. We hypothesized that inhibition of IL-17A or
the IL-17RA receptor, but not IL-17F, would lower
blood pressure and end-organ damage in a mouse
model of Ang II–induced hypertension.
METHODS
ANIMALS AND BLOOD PRESSURE MEASUREMENT.
Wild-type C57BL/6J mice were purchased from Jack-
son Laboratories (Bar Harbor, Maine). All protocols
were approved by the Institutional Animal Care and
Use Committee at Vanderbilt University. At approxi-
mately 10 to 12 weeks of age, osmotic minipumps
(Alzet, Model 2004, Cupertino, California) were
implanted subcutaneously for infusion of Ang II (490
ng/kg/min). Blood pressure was measured at baseline
and weekly during the 4 weeks of Ang II infusion
FIGURE 1 Angiotensin II Increases IL-17A– and IL-17F–Producing T Cells in Mouse Kidneys and Aortae
(A) Representative ﬂow cytometry analysis of renal and aortic T cells isolated from mice after 28 days of vehicle (Sham) or angiotensin II
(Ang II) infusion. (B)Quantiﬁcationof the total numberof interleukin (IL)-17A–or IL-17F–producing cells in kidneysandaortae (n¼5 to6pergroup).
Data were analyzed using Student t test and expressed as mean  SEM. *p < 0.05; **p < 0.01; ***p < 0.001 vs. WT/Sham. WT ¼ wild type.
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608using a computerized, noninvasive, tail-cuff system
(MC4000 Blood Pressure Analysis System, Hatteras
Instruments, Cary, North Carolina). Mice were sacri-
ﬁced at the end of all experiments by CO2 inhalation.
ANTIBODY TREATMENTS. Two weeks after induction
of hypertension with Ang II infusion, mice wererandomly allocated to the following 5 experimental
groups: 1) control mouse IgG1 antibody (mouse IgG1 K
isotype control functional grade puriﬁed, Clone
P3.6.2.8.1 [eBioscience, San Diego, California] or
mouse IgG1, PL-31545 [Amgen, Thousand Oaks, Cali-
fornia]); 2) control rat IgG1 antibody (rat IgG1 K
FIGURE 2 gd T Cells and TH17 Cells are the Major Sources of IL-17A and IL-17F in the Kidney and Vasculature Following Ang II Infusion
(A) Representative example of ﬂow cytometry gating strategy for the quantiﬁcation of IL-17A–producing CD3þ T cells in the kidney of an Ang II–treated mouse. A similar
strategy was used for IL-17F and for aortic samples. (B) Quantiﬁcation of the integrated mean ﬂuorescence intensity (iMFI) of IL-17A– or IL-17F–producing subsets of T
cells (gd T cell receptor [TCR]þ, CD4þ, CD8þ, and other double-negative T cells [other DN]). Data were analyzed using Student t test and expressed in arbitrary units
(A.U.) as mean  SEM (n ¼ 5 to 6 per group). *p < 0.05; **p < 0.01; ***p < 0.001 versus WT/Sham. Abbreviations as in Figure 1.
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FIGURE 3 Monoclonal Antibodies to IL-17A or the IL-17RA
Receptor Subunit, But Not IL-17F, Lowers Blood Pressure
in Response to Ang II Infusion
Systolic blood pressure was measured at baseline and weekly
during 28 days of Ang II infusion. Arrows indicate timing of
antibody administration. Data are expressed as mean  SEM and
were analyzed at day 28 using 1-way analysis of variance fol-
lowed by Holm-Sidak post hoc test (n ¼ 7 to 20 per group).
***p < 0.001 vs. mouse IgG1. Ab ¼ antibody; other abbreviations
as in Figures 1 and 2.
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610isotype control functional grade puriﬁed, Clone
eBRG1 [eBioscience]); 3) IL-17A neutralizing antibody
(mouse anti-mouse IL-17A functional grade puriﬁed,
Clone eBioMM17F3 [eBioscience]); 4) IL-17F neutral-
izing antibody (rat anti-mouse IL-17F functional
grade puriﬁed, Clone RN17 [eBioscience]); and 5)
IL-17RA receptor antagonist (murine muIL-17RA-
M751, PL-31280 [Amgen]). Mice were injected intra-
peritoneally with 100 mg of antibodies twice
weekly during the last 2 weeks of Ang II infusion
(days 16, 19, 22, and 25). This dose and frequency was
chosen based on prior studies from our group and
others (17–20).
FLOW CYTOMETRY. Mice were euthanized with CO2
and transcardially perfused with phosphate buffered
saline–heparin (10 U/ml) before the collection of or-
gans. Kidney and thoracic aortic leukocytes were
isolated as described previously (21) and stained us-
ing the antibodies listed in Supplemental Table 1.
For intracellular staining, single-cell suspensions
of kidneys or the whole aortae in RPMI medium
supplemented with 5% fetal bovine serum were
stimulated with 2 ml of BD Leukocyte Activation
Cocktail (ionomycin, brefeldin A, and phorbol
myristic acetate) at 37C for 3 h. Cells were then
stained using the antibodies listed in Supplemental
Table 2.
ENZYME-LINKED IMMUNOSORBENT ASSAYS. Urine
was collected over a 24-h period at baseline, after
2 weeks, and after 4 weeks of Ang II infusion by
placement ofmice inmetabolic cages. Urinary albumin
concentrations were determined by enzyme-linked
immunosorbent assay (ELISA) (Exocell M, Exocell,
Philadelphia, Pennsylvania). Total urinary volumewas
recorded and multiplied by the albumin concentration
to determine the daily albumin excretion rate. Renal
transforming growth factor beta (TGFb) levels were
quantiﬁed from whole-kidney homogenates using a
mouse/rat/porcine/canine TFG-b1 Quantikine ELISA
kit (R&D Systems, Minneapolis, Minnesota) and
normalized to total kidney weight.
STATISTICAL ANALYSES. Data are expressed as
mean  SEM. The assumption of normality was made
because most continuous physical characteristics
follow a Gaussian distribution. Differences between
2 groups were compared using the Student t test.
Differences between 3 or more groups were compared
using 1-way analysis of variance (ANOVA) followed
by the Holm-Sidak post hoc test. Blood pressure and
albuminuria data were analyzed at day 28 using
1-way ANOVA followed by the Holm-Sidak post hoc
test. p < 0.05 was considered signiﬁcant.RESULTS
ANG II–INDUCED HYPERTENSION IS ASSOCIATED
WITH INCREASED T-CELL PRODUCTION OF IL-17A
AND IL-17F IN THE KIDNEY AND VASCULATURE.
We ﬁrst determined whether there was an increase in
IL-17A– and IL-17F–producing T cells in the kidney and
aortae of mice following 4 weeks of Ang II (490 ng/kg/
min) infusion. Intracellular staining indicated that
Ang II–induced hypertension was associated with a
signiﬁcant increase in CD3þIL-17Aþ and CD3þIL-17Fþ
cells in the kidney and aortae (Figure 1). To determine
the speciﬁc T-cell subsets producing IL-17A and
IL-17F, we employed the gating strategy depicted in
Figure 2A. CD3þ T cells were selected from the live
singlets. Intracellular staining with IL-17A or IL-17F
identiﬁed the total T cells producing these cytokines.
Gamma delta (gd) T cells possess a distinct T-cell re-
ceptor that can be distinguished from conventional
alpha beta (ab) T-cell receptors by ﬂow cytometry.
We therefore gated on the presence of the gd T-cell
receptor to quantify the IL-17–producing gd T cells.
Finally, we gated on the gd T-cell receptor negative
cells (which are presumably conventional ab T cells)
and further classiﬁed these into CD4þ, CD8þ, or
other double-negative cells. To determine the relative
T-cell subset contribution to IL-17A and IL-17F pro-
duction, we used the integrated mean ﬂuorescence
FIGURE 4 Monoclonal Antibodies to IL-17A or the IL-17RA Receptor Subunit Reduce Renal and Vascular Inﬂammation in Response to Ang II Infusion
Quantiﬁcation of total leukocytes (CD45þ cells), total T lymphocytes (CD3þ cells), and T-cell subsets (CD4þ and CD8þ) per kidney (A) or thoracic aorta (B) in mice infused
with Ang II for 4 weeks and treated with either IL-17A neutralizing antibody, IL-17RA receptor antagonist, or corresponding mouse IgG1 isotype control twice
weekly during the last 2 weeks of Ang II infusion. Data were analyzed using 1-way analysis of variance followed by Holm-Sidak post hoc test and expressed as
mean  SEM (n ¼ 12 to 20 per group). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. mouse IgG1. Abbreviations as in Figures 1 to 3.
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611intensity, which is obtained by multiplying the num-
ber of cells expressing a particular marker with the
mean ﬂuorescence intensity in that channel (22). We
found that gd T cells and CD4þ TH17 cells are the pre-
dominant sources of IL-17A and IL-17F in the kidney
and aorta, particularly following Ang II infusion
(Figure 2B).
ADMINISTRATION OF MONOCLONAL ANTIBODIES
TO IL-17A OR THE IL-17RA RECEPTOR SUBUNIT, BUT
NOT IL-17F, LOWERS BLOOD PRESSURE IN
RESPONSE TO ANG II INFUSION. Monoclonal anti-
bodies to human IL-17A, IL-17F, and the IL-17RA
receptor subunit are in various phases of develop-
ment, testing, and FDA approval for the treatment of
psoriasis and related IL-17A–mediated autoimmune
diseases. As proof of concept, we sought to determine
whether these antibodies would have a beneﬁcial
effect in a mouse model of hypertension. Ang II was
infused for 4 weeks into wild-type C57Bl/6J mice.
During the ﬁnal 2 weeks of Ang II infusion, antibodies
to IL-17A, IL-17F, IL-17RA, or corresponding IgG1
control antibodies were injected intraperitoneally
twice weekly as depicted in Figure 3. Administration
of monoclonal antibodies to IL-17A and IL-17RA
resulted in a 30 mm Hg decrease in blood pressure.
By contrast, the anti–IL-17F antibody and both
IgG1 control antibodies had no effect on bloodpressure during the ﬁnal 2 weeks of Ang II infusion
(Figure 3). It should be noted that although blood
pressure was reduced from approximately 180 mm Hg
to 150 mm Hg with anti–IL-17A and anti–IL-17RA
antibodies, the pressures were still elevated
compared with the baseline blood pressures of 110 to
120 mm Hg.
ADMINISTRATION OF MONOCLONAL ANTIBODIES
TO IL-17A OR THE IL-17RA RECEPTOR SUBUNIT, BUT
NOT IL-17F, REDUCES RENAL AND VASCULAR
INFLAMMATION. To determine the effect of IL-17
blockade on renal and vascular inﬂammation, Ang II
was infused for 4 weeks, and monoclonal antibodies
to IL-17A, IL-17F, IL-17RA, or corresponding IgG1
control antibodies were injected intraperitoneally
twice weekly during the last 2 weeks of Ang II infusion
as described in the preceding text. Flow cytometry was
performed on single-cell suspensions from 1 kidney
and the thoracic aorta to quantify degree of inﬂam-
mation. Surface stainingwas performed for CD45 (total
leukocytes), CD3 (total T cells), CD4 (T helper cells),
CD8 (cytotoxic T cells), and F4/80 (a monocyte/
macrophage marker). Mice treated with mono-
clonal antibodies to IL-17A and IL-17RA exhibited
signiﬁcantly reduced levels of total leukocytes, total
T cells, CD4þ T cells, and CD8þ T cells in the kidney
compared withmice treated with a corresponding IgG1
FIGURE 5 Monoclonal Antibodies to IL-17F Have No Effect on Renal and Aortic Inﬂammation
Quantiﬁcation of total leukocytes (CD45þ cells), total T lymphocytes (CD3þ cells), and T-cell subsets (CD4þ and CD8þ) per kidney (A) or
thoracic aorta (B) in mice infused with Ang II for 4 weeks and treated with either IL-17F neutralizing antibody or corresponding rat IgG1 isotype
control twice weekly during the last 2 weeks of Ang II infusion. Data were analyzed using Student t test and expressed as mean  SEM (n ¼ 12
per group). Abbreviations as in Figures 1 to 3.
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612control antibody (Figure 4A). Of note, there was no
change in the number of double-negative T cells or
monocytes/macrophages in the kidney with either of
these antibody treatments (Supplemental Figure 1A).
Similar results were observed in the aorta (Figure 4B,
Supplemental Figure 1B). By contrast, mice that
received the IL-17F antibody exhibited no change in
total leukocyte, T-cell, or monocyte/macrophage
numbers in the kidney or aorta compared to IgG1-
treated mice, consistent with a lack of blood pressure
effect with this antibody (Figure 5, Supplemental
Figure 2). To conﬁrm that the administration of iso-
type control antibodies did not affect renal or vascular
immune cell inﬁltration, we compared levels of
total leukocytes, total T cells, T-cell subsets, and
monocytes/macrophages in untreated wild-type
mice following 4 weeks of Ang II infusion to mice
that received mouse or rat IgG1 during the last 2 weeks
of Ang II infusion and found no signiﬁcant differences
in the numbers of these cells in both the kidney and
aorta (data not shown).
ADMINISTRATION OF MONOCLONAL ANTIBODIES
TO IL-17A, IL-17F, OR IL-17RA BLUNTS THE
PROGRESSION OF ALBUMINURIA IN RESPONSE TO
ANG II INFUSION. To assess the effect of IL-17
blockade on renal injury, 24-h urine was collected at
baseline, after 2 weeks of Ang II infusion (beforeantibody administration), and after 4 weeks of Ang II
infusion (with twice weekly antibody injections
given between weeks 2 and 4). Urinary albumin con-
centration was measured by ELISA. At baseline, there
was very little albuminuria and no signiﬁcant differ-
ences among the groups. Albuminuria increased
markedly after 2 weeks of Ang II infusion. Interest-
ingly, treatment with any of the IL-17 antibodies,
including the IL-17F antibody, halted the progression
of albuminuria, whereas mice that received either
control antibody had continued progression of albu-
minuria (Figure 6A). Thus, blockade of IL-17 signaling
protects from Ang II–induced glomerular injury.
ADMINISTRATION OF MONOCLONAL ANTIBODIES
TO IL-17A OR THE IL-17RA RECEPTOR SUBUNIT, BUT
NOT IL-17F, REDUCES RENAL TGFb LEVELS. Renal
ﬁbrosis is another hallmark of renal damage from
hypertension and is mediated by TGFb signaling (23).
To assess renal ﬁbrosis, we measured TGFb levels
from whole-kidney homogenates following 4 weeks of
Ang II infusion. Antibodies to IL-17A, IL-17RA, IL-17F,
or corresponding isotype controls were injected
twice weekly during the last 2 weeks of Ang II infusion
as depicted in Figure 6A. Kidneys from mice that
did not receive Ang II or antibodies were used as a
reference control (untreated). Renal TGFb1 levels
markedly increase in response to Ang II infusion in
FIGURE 6 Effect of Monoclonal Antibodies to IL-17A, IL-17F,
or the IL-17RA Receptor Subunit on Glomerular Injury and
Renal Fibrosis in Response to Ang II Infusion
(A) Glomerular injury was assessed by quantifying 24-h urinary
excretion of albumin at baseline and after 14 or 28 days of Ang II
infusion. Arrows indicate timing of antibody administration. Data
are expressed as mean  SEM and were analyzed at day 28 by
1-way analysis of variance followed by Holm-Sidak post hoc test
(n ¼ 7 to 15 per group). *p < 0.05; ***p< 0.001; ****p< 0.0001
vs. corresponding IgG1 control. (B) Renal ﬁbrosis was assessed by
quantifying transforming growth factor b1 (TGFb1) from renal
homogenates. Data from mice that received no antibodies and no
Ang II (Untreated) are shown as a reference control. The other
groups were infused with Ang II for 28 days and treated with the
indicated antibodies twice weekly during the last 2 weeks of Ang II
infusion. Data were analyzed by 1-way analysis of variance
followed by Holm-Sidak post hoc test and expressed as mean 
SEM (n¼ 5 per group). *p< 0.05; ***p< 0.001; ****p< 0.0001.
Abbreviations as in Figures 1 to 3.
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613isotype control–treated mice. Antibodies to IL-17A or
IL-17RA, but not IL-17F, signiﬁcantly reduced TGFb
levels (Figure 6B). Thus, inhibition of IL-17A and
IL-17RA reduces blood pressure, renal/vascular
inﬂammation, and markers of renal injury and
ﬁbrosis.DISCUSSION
We and others have previously demonstrated that
the proinﬂammatory cytokine IL-17A is elevated in
hypertensive animals and humans, and that IL-17A
promotes sustained hypertension, as well as renal
and vascular dysfunction (3–6,24). However, the spe-
ciﬁc T-cell subsets that contribute to IL-17 production
in the kidney and vessels were previously unknown.
From a translational perspective, there are few data on
whether neutralizing antibodies to IL-17A, IL-17F, or
the IL-17RA receptor subunit can lower blood pressure
and ameliorate hypertension-associated end-organ
damage. In the current study, we show that innate-like
gd T cells and CD4þ TH17 cells are the primary sources
of IL-17A and IL-17F in the aortae and kidneys of
Ang II–infused mice. Importantly, we show that acute
pharmacological inhibition of IL-17A or the IL-17RA
receptor subunit can reduce blood pressure by w30
mm Hg, attenuate renal/vascular inﬂammation, and
decrease markers of renal injury and ﬁbrosis, making
these potentially attractive therapeutic options for the
management of hypertension.
Our ﬁnding that gd T cells are a major source of IL-17
isoforms in the aorta and kidney of hypertensive ani-
mals is consistent with a recent report by Li et al. (14)
showing that gd T cells are a major source of IL-17A in
the heart and contribute to Ang II–induced cardiac
ﬁbrosis and injury. Similar to our ﬁndings, these au-
thors showed that whereas gd T cells were one of the
smallest cardiac inﬁltrating T-cell populations, their
secretion of IL-17A was the greatest. These uncon-
ventional T cells are particularly interesting in that
they do not seem to require antigen processing and
major histocompatibility complex presentation of
peptide antigens. Moreover, they play an important
role in the recognition of lipid antigens and may be
triggered by alarm signals such as heat shock proteins.
In autoimmune disease, these cells appear to be
driven by self molecules that arise during inﬂamma-
tion. In many inﬂammatory processes, they appear to
be the dominant early source of IL-17 with antigen-
speciﬁc CD4þ TH17 cells developing later and
contributing to the sustained immune response
(13,25). Further studies are needed to determine the
role of gd T cells in hypertension and whether speciﬁc
pharmacological inhibition of these cells may prove
beneﬁcial in treating hypertensive end-organ damage.
In an elegant study, Amador et al. (19) demon-
strated that spironolactone treatment prevented TH17
cell activation and increased numbers of anti-
inﬂammatory T regulatory cells in rats in response
to deoxycorticosterone acetate and high-salt diet
(DOCA-salt). The effect of spironolactone on gd T cells
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614was not investigated in this study, but it does raise
the question of whether the beneﬁcial effects of spi-
ronolactone, one of the most effective drugs on the
market for resistant hypertension, could be due to
inhibition of the IL-17A axis. Consistent with our re-
sults, these authors showed that administration of an
anti–IL-17A antibody to DOCA-salt–treated rats low-
ered blood pressure by w20 mm Hg and reduced the
expression of some proﬁbrotic and proinﬂammatory
mediators in the heart and kidney (19). However, in
this study, the authors noted no improvement in
proteinuria with anti–IL-17A treatment. Our ﬁndings
conﬁrm and extend this study by using a different
animal model of hypertension and examining the
effects of inhibition of IL-17A, IL-17F, and the IL-17RA
receptor. We found that inhibition of both IL-17A and
the IL-17RA receptor signiﬁcantly lowered blood
pressure and end-organ damage from hypertension,
including inﬂammation, albuminuria, and renal TGFb
levels.
The mechanism by which IL-17A promotes immune
cell inﬁltration into the aorta or kidney is likely
through the up-regulation of chemokines that attract
all types of immune cells (not just IL-17–producing
immune cells) into the target organ. For example,
Paust et al. (26) showed that in mouse mesangial
cells, IL-17A up-regulates CCL2, CCL3, and CCL20—
chemokines involved in the recruitment of T cells and
monocytes. We previously showed that IL-17A in-
duces the expression of a number of chemokines such
as CCL8, CXCL2, and CCL7 in human aortic smooth
muscle cells (3). Thus, by blocking the effects of IL-17,
we reduced overall inﬂammation in the aorta and
kidney. However, double-negative cells were not
reduced (Supplemental Figure 1). These cells are a
small subset of the total immune cell population in
these organs, so it is possible that we were not able to
detect a decrease or there was no signiﬁcant decrease
in this small population of cells. Moreover, there may
be a feedback mechanism in effect, by which double-
negative cell numbers are maintained to compensate
for the reduction in IL-17 signaling by the antibodies.
Of note, the anti–IL-17F antibody caused a
modest reduction in albuminuria without a reduction
in blood pressure or other parameters of renal
inﬂammation/ﬁbrosis. We previously showed that
mice genetically deﬁcient in IL-17F had no reduction in
Ang II–induced hypertension or albuminuria (6).
Moreover, we showed in that study that IL-17A, but not
IL-17F, regulates the renal sodium chloride cotrans-
porter (NCC) through a serum and glucocorticoid
regulated kinase 1 (SGK1) pathway. Taken together, IL-
17A signaling through the IL-17RA subunit appears to
play a critical role in Ang II–induced hypertension andend-organ damage with little or no contribution of the
IL-17F isoform.
Given that IL-17A and IL-17F are so closely related
and signal through the same receptor complex, the
reason for the differential effects of IL-17A and IL-17F
in hypertension is unclear. However, there is prece-
dence for this in other chronic inﬂammatory diseases.
For example, in a chronic asthma model, IL-17A
positively regulates asthmatic allergic responses,
whereas IL-17F has a negative role. In dextran sulfate
sodium–induced colitis, IL-17F–deﬁcient mice exhibit
reduced colitis, whereas IL-17A deﬁciency is associ-
ated with more severe disease (10). Thus, it is
important to determine the precise role of these
related cytokines in hypertensive models.
Our results are timely and clinically relevant
because there are currently several monoclonal
antibody–based drugs that are in various phases of
development, testing, and FDA approval for the
treatment of psoriasis and other IL-17A–mediated
autoimmune diseases (reviewed in Beringer et al. [9]).
Speciﬁcally, secukinumab has recently been FDA
approved for psoriasis, psoriatic arthritis, and anky-
losing spondylitis. Brodalumab (a human monoclonal
anti–IL-17RA antibody) showed promising results in
Phase III clinical trials for psoriasis. For our study, we
used a murine anti–IL-17RA antibody (a generous
gift from Amgen). Interestingly, there is strong epide-
miological evidence for a link between psoriasis and
hypertension (27–29), which may be due to a shared
pathophysiology of increased IL-17A signaling and
inﬂammation. Psoriasis patients tend to have more
difﬁcult-to-control hypertension compared with
their non-psoriatic counterparts (27). Through a
population-based study in the United Kingdom,
Takeshita et al. (29) found that among patients with
hypertension, psoriasis is associated with a greater
likelihood of uncontrolled hypertension.
STUDY LIMITATIONS. One limitation of this study is
that we only utilized a mouse model of Ang II-
induced hypertension. Further studies are needed to
determine whether our results are applicable to other
animal models of hypertension and ultimately to
human hypertension. Another limitation is that we
did not have a vehicle infused (normotensive) control
group for our ﬂow cytometry experiments. Thus,
while we observed a reduction in renal and vascular
inﬂammation in mice treated with anti-IL-17A and
anti-IL-17RA antibodies during the last two weeks
of a 4- week Ang II infusion protocol, we do not know
if the levels of inﬂammation in these tissues returned
to baseline. Finally, we only tested one dose, fre-
quency, and duration of antibody administration.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: The major T-cell
sources of IL-17A and IL-17F in the kidney and vasculature in
response to angiotensin II–induced hypertension are specialized
subsets of innate-like gd T cells and CD4þ TH17 cells. Monoclonal
antibodies to IL-17A or the IL-17RA receptor subunit lower blood
pressure, attenuate renal/vascular inﬂammation, and decrease
markers of renal injury and ﬁbrosis in a mouse model of
hypertension.
TRANSLATIONALOUTLOOK:Monoclonal antibodies to IL-17
isoformsand the IL-17 receptor are invariousphasesofdevelopment,
clinical testing, and FDA approval for the treatment of psoriasis and
related autoimmune disorders. There is a strong epidemiological link
between psoriasis and hypertension severity. Thus, this new class of
drugs could have an added beneﬁt of reducing blood pressure and
end-organ damage in psoriasis patients. Importantly, our results
suggest that these drugs could also have a beneﬁt in the manage-
ment of hypertension in the general population. Thus it is imperative
that small clinical trials and eventually larger randomized studies are
conducted to determine the safety and efﬁcacy of these drugs in
human hypertension.
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615Thus, it is unknown whether alternative doses, fre-
quency, and treatment durations would result in
greater reductions in blood pressure and end-organ
damage.
CONCLUSIONS
Our results suggest that anti–IL-17A/RA–based thera-
pies for psoriasis could have a dual beneﬁt by also
reducing hypertension severity and cardiovascular
risk. Moreover, the beneﬁt of these IL-17A/RA in-
hibitors could apply to the general hypertensive
population as well. Of course, the risk-to-beneﬁt ratio
of these drugs needs to be determined in a cardio-
vascular disease cohort. There is an increased risk
of mild-to-moderate infections in patients treated
with IL-17 inhibitors. In addition, it should be noted
that in a few experimental models of renal
injury, IL17 inhibition has been shown to exacerbate
disease (30–32). Nevertheless, our provocative data
support the use of IL-17A/RA inhibitors in pilot
proof-of-principle clinical trials in humans for the
treatment of hypertension and its devastating
complications.
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